Unlabeled uses: Prevention of recurrent TIAs, prevention of recurrent MI, adjunct to therapy in small-cell carcinoma of the lung.Prophylaxis of systemic embolization after acute MI.Pulmonary embolism, treatment, and prophylaxis.Treatment of thromboembolic complications of atrial fibrillation with embolization, and cardiac valve replacement.Venous thrombosis and its extension, treatment, and prophylaxis.No effects on established thrombus but further extension of the clot can be prevented. Warfarin inhibits synthesis of vit K-dependent coagulation factors VII, IX, X and II and anticoagulant protein C and its cofactor protein S.Lower doses are usually needed begin with smaller doses than those recommended for adults and closely monitor PT ratio or INR.For maintenance, 2–10 mg/day PO based on PT ratio or INR. Dosages are the same for oral and IV forms. IV use is reserved for situations in which oral warfarin is not feasible. Brand Name: Apo-Warfarin (CAN), Coumadin, Gen-Warfarin (CAN)Ĭlassification: Oral anticoagulant, Coumarin derivativeĪvailable forms :Tablets-1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg powder for injection-5.4 mg reconstitutes to 2 mg/mLĭosages :Adjust dosage according to the one-stage PT to achieve and maintain 1.5–2.5 times the control value or prothrombin activity 20%–30% of normal PT ratio of 1.3–1.5 or INR of 2–3.

Warfarin sodium overdose antidote